FNFDCM
IBB icon

Folger Nolan Fleming Douglas Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Folger Nolan Fleming Douglas Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6M Sell
61,030
-467
-0.8% -$80.3K 0.95% 30
2026
Q1 		$10.4M Sell
61,497
-248
-0.4% -$42.4K 0.93% 30
2025
Q4 		$10.4M Sell
61,745
-595
-1% -$96.6K 1.07% 25
2025
Q3 		$9M Sell
62,340
-277
-0.4% -$37.8K 0.94% 32
2025
Q2 		$7.92M Sell
62,617
-1,495
-2% -$184K 0.88% 34
2025
Q1 		$8.2M Sell
64,112
-1,148
-2% -$156K 0.92% 32
2024
Q4 		$8.63M Sell
65,260
-1,400
-2% -$197K 0.9% 32
2024
Q3 		$9.71M Buy
66,660
+308
+0.5% +$44.6K 0.96% 29
2024
Q2 		$9.11M Buy
66,352
+675
+1% +$90.1K 0.93% 30
2024
Q1 		$9.01M Buy
65,677
+291
+0.4% +$39.7K 0.92% 30
2023
Q4 		$8.88M Sell
65,386
-2,444
-4% -$298K 0.97% 26
2023
Q3 		$8.29M Buy
67,830
+663
+1% +$84.3K 0.97% 28
2023
Q2 		$8.53M Buy
67,167
+928
+1% +$121K 0.93% 29
2023
Q1 		$8.55M Sell
66,239
-601
-0.9% -$78.7K 1% 27
2022
Q4 		$8.82M Sell
66,840
-116
-0.2% -$15K 1.06% 31
2022
Q3 		$7.83M Buy
66,956
+507
+0.8% +$63K 1.07% 27
2022
Q2 		$7.82M Buy
66,449
+37
+0.1% +$4.39K 1.03% 29
2022
Q1 		$8.65M Buy
66,412
+2,590
+4% +$337K 0.97% 30
2021
Q4 		$9.74M Buy
63,822
+1,281
+2% +$198K 1.06% 26
2021
Q3 		$10.1M Buy
62,541
+1,898
+3% +$319K 1.22% 24
2021
Q2 		$9.92M Buy
60,643
+2,484
+4% +$383K 1.15% 24
2021
Q1 		$8.76M Buy
58,159
+1,726
+3% +$274K 1.06% 25
2020
Q4 		$8.55M Buy
56,433
+1,060
+2% +$151K 1.13% 23
2020
Q3 		$7.5M Buy
55,373
+2,122
+4% +$288K 1.12% 23
2020
Q2 		$7.28M Sell
53,251
-89
-0.2% -$11.3K 1.18% 23
2020
Q1 		$5.75M Sell
53,340
-1,471
-3% -$169K 1.15% 27
2019
Q4 		$6.61M Buy
54,811
+260
+0.5% +$29K 0.96% 33
2019
Q3 		$5.43M Buy
54,551
+825
+2% +$86.4K 0.84% 35
2019
Q2 		$5.86M Buy
53,726
+2,025
+4% +$215K 0.88% 34
2019
Q1 		$5.78M Buy
51,701
+2,380
+5% +$261K 0.86% 33
2018
Q4 		$4.76M Buy
49,321
+990
+2% +$105K 0.78% 35
2018
Q3 		$5.89M Buy
48,331
+1,184
+3% +$139K 0.83% 30
2018
Q2 		$5.18M Buy
47,147
+1,735
+4% +$186K 0.75% 32
2018
Q1 		$4.85M Buy
45,412
+1,455
+3% +$161K 0.72% 36
2017
Q4 		$4.69M Buy
43,957
+1,165
+3% +$125K 0.65% 36
2017
Q3 		$4.76M Buy
42,792
+2,220
+5% +$237K 0.69% 31
2017
Q2 		$4.19M Buy
40,572
+765
+2% +$75.3K 0.64% 36
2017
Q1 		$3.89M Buy
39,807
+2,694
+7% +$258K 0.58% 40
2016
Q4 		$3.58M Hold
37,113
– – 0.59% 40
2016
Q3 		$3.58M Buy
37,113
+21
+0.1% +$2K 0.59% 40
2016
Q2 		$3.18M Buy
37,092
+1,290
+4% +$116K 0.55% 46
2016
Q1 		$3.11M Buy
35,802
+4,284
+14% +$383K 0.56% 43
2015
Q4 		$3.55M Buy
31,518
+1,332
+4% +$145K 0.63% 37
2015
Q3 		$3.05M Buy
30,186
+630
+2% +$75.6K 0.63% 39
2015
Q2 		$3.63M Sell
29,556
-570
-2% -$68.2K 0.67% 35
2015
Q1 		$3.45M Buy
30,126
+315
+1% +$34.7K 0.6% 38
2014
Q4 		$3.01M Buy
29,811
+570
+2% +$55.4K 0.52% 44
2014
Q3 		$2.67M Buy
29,241
+1,020
+4% +$89.5K 0.48% 46
2014
Q2 		$2.42M Buy
28,221
+1,110
+4% +$87.5K 0.44% 50
2014
Q1 		$2.14M Buy
27,111
+7,050
+35% +$587K 0.44% 51
2013
Q4 		$1.52M Buy
20,061
+3,240
+19% +$230K 0.27% 64
2013
Q3 		$1.18M Sell
16,821
-570
-3% -$37.3K 0.23% 74
2013
Q2 		$1.01M Buy
+17,391
New +$1.01M 0.21% 73

Other funds holding IBB

GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
RFA
Reyes Financial Architecture San Diego, California $179M AUM 31.17% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
MCG
McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
SCA
Southern Capital Advisors Jackson, Tennessee $239M AUM 22.42% 1-Year Est. Return
HCMG
Howard Capital Management Group Los Angeles, California $1.64B AUM 24.96% 1-Year Est. Return

Folger Nolan Fleming Douglas Capital Management's IBB Position: Q2 2026 in Review

Folger Nolan Fleming Douglas Capital Management reduced its iShares Biotechnology ETF (IBB) stake by 0.76% in Q2 2026, selling an estimated $80.3K and leaving 61,030 shares worth $11.6M. The position accounts for 0.95% of the portfolio, ranked #30.

Folger Nolan Fleming Douglas Capital Management first reported a position in IBB in Q2 2013 and has held it in 53 quarters since. 158 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Folger Nolan Fleming Douglas Capital Management held 61,030 shares of iShares Biotechnology ETF worth $11.6M as of Q2 2026.
  • Folger Nolan Fleming Douglas Capital Management sold 467 iShares Biotechnology ETF shares in Q2 2026, an estimated $80.3K.
  • iShares Biotechnology ETF made up 0.95% of Folger Nolan Fleming Douglas Capital Management's portfolio in Q2 2026, its #30 holding.
  • Folger Nolan Fleming Douglas Capital Management first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 53 quarters since.
  • 158 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Folger Nolan Fleming Douglas Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.